Pivekimab sunirine is under clinical development by ImmunoGen and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pivekimab sunirine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pivekimab sunirine overview
IMGN-632 is under development for the treatment of CD123-positive hematologic malignancies include blastic plasmacytoid dendritic cell neoplasm, myeloproliferative disorders, acute lymphocytic leukemia, myelodysplastic syndrome, relapsed and refractory acute myeloid leukemia. It is administered through the intravenous route. The drug candidate is a conjugate of a humanized anti-CD123 antibody with indolinobenzodiazepine payload that alkylates DNA.
It was also under development for the treatment of chronic myelocytic leukemia (CML, chronic myeloid leukemia), chronic myelomonocytic leukemia (CMML).
ImmunoGen overview
ImmunoGen, a subsidiary of AbbVie Inc, is a clinical-stage biotechnology company primarily focused on the development of targeted cancer therapies. The company specializes in the creation of Antibody-Drug Conjugates (ADCs), which are designed to selectively target and kill cancer cells. ImmunoGen‘s lead product, Mirvetuximab Soravtansine-gynx (ELAHERE) is developed for the treatment of ovarian cancer. The company’s pipeline product candidates include mirvetuximab soravtansine for the treatment of platinum-resistant ovarian cancer; Anti-CD123 for AML, and pivekimab sunirine for blastic plasmacytoid dendritic cell neoplasm (BPDCN); IMGC936, the company’s product candidate for a range of solid tumors; and IMGN151, its next-generation anti-FRa candidate in the preclinical development stage. The company has operations in the US, Ireland, and the UK. ImmunoGen is headquartered in Waltham, Massachusetts, the US.
For a complete picture of Pivekimab sunirine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
